Lindkvist Madelene, Göthlin Eremo Anna, Paramel Geena Varghese, Anisul Haque Sheikh, Rydberg Millrud Camilla, Rattik Sara, Grönberg Caitríona, Liberg David, Sirsjö Allan, Fransén Karin
Cardiovascular Research Centre, Faculty of Medicine and Health Örebro University Örebro Sweden.
School of Medical Sciences, Faculty of Medicine and Health Örebro University Örebro Sweden.
J Am Heart Assoc. 2025 May 20;14(10):e039557. doi: 10.1161/JAHA.124.039557. Epub 2025 May 15.
Blockade of IL1RAP (interleukin 1 receptor associated protein) was recently shown to reduce atherosclerosis in mice, but the effect on human vascular cells is largely unknown. Targeting the IL1RAP coreceptor represents a novel strategy to block the IL1RAP-dependent cytokines IL (interleukin)-1, IL-33, and IL-36. In the present study, we aimed to evaluate the role of novel antibodies targeting IL1RAP to reduce the effects of IL-1β, IL-33, or IL-36γ in human vascular cells.
Expression of IL1RAP was observed in human atherosclerotic plaques by immunohistochemistry and microarray and in endothelial cells by flow cytometry. Endothelial cells were cultured with IL-1β, IL-33, or IL-36γ cytokines with or without IL1RAP antibodies and analyzed with Olink proteomics, ELISA, Western blot, and real-time quantitative polymerase chain reaction. The functional effect of IL1RAP antibodies on endothelial cells were analyzed with adhesion and permeability assays.
Olink proteomics showed inhibition of the inflammatory proteins LIF (leukemia inhibitory factor), OPG (osteoprotegerin), CCL4 (C-C motif chemokine ligand 4), and MCP-3 (monocyte chemoattractant protein 3) by IL1RAP-blockade in endothelial cells after IL-1β stimulation. In addition, the IL1RAP antibodies inhibited IL-1β, and IL-33 induced IL-6 and IL-8 secretion. Secretion of MCP-1 (monocyte chemoattractant protein 1) was induced by IL-1β, IL-33, and IL-36γ, and subsequently was inhibited by IL1RAP antibodies. Similar effects were found on mRNA expression level. Endothelial expression of the adhesion markers , and were significantly reduced by IL1RAP antibodies, and neutrophil adhesion to endothelial cells induced by IL-1β and IL-33 was reduced by IL1RAP blockade. In human atherosclerotic lesions, expression correlated with markers of inflammation like , and .
IL1RAP-targeting antibodies can reduce the expression of inflammatory cytokines and markers of adhesion in endothelial cells, which may be of importance for future putative targeted treatments against cardiovascular disease.
近期研究表明,阻断白细胞介素1受体相关蛋白(IL1RAP)可减轻小鼠动脉粥样硬化,但对人血管细胞的影响尚不清楚。靶向IL1RAP共受体是一种阻断依赖IL1RAP的细胞因子白细胞介素(IL)-1、IL-33和IL-36的新策略。在本研究中,我们旨在评估靶向IL1RAP的新型抗体在减轻人血管细胞中IL-1β、IL-33或IL-36γ作用方面的作用。
通过免疫组织化学和微阵列观察人动脉粥样硬化斑块中IL1RAP的表达,通过流式细胞术观察内皮细胞中IL1RAP的表达。将内皮细胞与IL-1β、IL-33或IL-36γ细胞因子一起培养,添加或不添加IL1RAP抗体,然后用欧林蛋白质组学、酶联免疫吸附测定(ELISA)、蛋白质免疫印迹法和实时定量聚合酶链反应进行分析。通过黏附试验和通透性试验分析IL1RAP抗体对内皮细胞的功能作用。
欧林蛋白质组学显示,在IL-1β刺激后,阻断IL1RAP可抑制内皮细胞中炎症蛋白白血病抑制因子(LIF)、骨保护素(OPG)、C-C基序趋化因子配体4(CCL4)和单核细胞趋化蛋白3(MCP-3)的表达。此外,IL1RAP抗体可抑制IL-1β和IL-33诱导的IL-6和IL-8分泌。IL-1β、IL-33和IL-36γ可诱导单核细胞趋化蛋白1(MCP-1)分泌,随后IL1RAP抗体可抑制其分泌。在mRNA表达水平上也发现了类似的作用。IL1RAP抗体可显著降低黏附标志物、和在内皮细胞上的表达,阻断IL1RAP可减少IL-1β和IL-33诱导的中性粒细胞与内皮细胞的黏附。在人类动脉粥样硬化病变中,的表达与、和等炎症标志物相关。
靶向IL1RAP的抗体可降低内皮细胞中炎症细胞因子的表达和黏附标志物的表达,这可能对未来针对心血管疾病的靶向治疗具有重要意义。